Back to results
US 2016/0102129 A1Published application
Stable GLP-1 Based GLP-1/Glucagon Receptor Co-Agonists
AssigneeNovo Nordisk A/S
InventorsSteffen Reedtz-Runge, Ulrich Sensfuss, Thomas Kruse, Jane Spetzler, Henning Thoegersen, Christian W. Tornoee, Jesper F. Lau
Life of this patent
Estimating the term…
Abstract
New GLP-1 derivatives, compositions thereof and their use in medicine.
Claims21
A GLP-1 derivative comprising:
- (i) a polypeptide consisting of
- (SEQ ID NO:
- 2)
- Imp-X8-His-Gly-Thr-Phe-Thr-Ser-Asp-X16-Ser-X18-
- Tyr-Leu-Glu-X22-X23-Ala-Ala-X26-X27-Phe-Ile-
- Ala-Trp-Leu-X33-X34-X35-X36-X37,
- wherein
- X8 is Ala, Aib, Acb, or Gly;
- X16 is Val, Leu, (Ile), or Tyr;
- X18 is Lys or Arg;
- X22 is Gly, Ala, Glu, Lys, Arg, (Ser), or (Aib);
- X23 is Gln, Arg, or Lys;
- X26 is (Lys) or Arg;
- X27 is Glu or Lys;
- X33 is (Val), Leu, or Ile;
- X34 is Lys or Arg;
- X35 is Gly, Thr, Lys, or is absent;
- X36 is Ala, Gly, Lys, Ser, or is absent;
- and
- X37 is Gly or is absent;
- and
- (ii) a substituent comprising a lipophilic moiety and at least two negatively charged moieties, wherein one of said negatively charged moieties is distal of said lipophilic moiety;
- wherein said polypeptide optionally comprises a C-terminal amide;
- or a pharmaceutically acceptable salt and/or ester thereof.
21 more elements
A GLP-1 analogue comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, and 43;
- or a pharmaceutically acceptable salt, amide or ester thereof.
Dependencies are inferred from the claim text.